A detailed history of Morgan Stanley transactions in Exagen Inc. stock. As of the latest transaction made, Morgan Stanley holds 482,420 shares of XGN stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
482,420
Previous 482,420 -0.0%
Holding current value
$1.21 Million
Previous $767,000 14.47%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Aug 16, 2024

SELL
$1.42 - $2.3 $2,130 - $3,449
-1,500 Reduced 0.31%
482,420 $767,000
Q1 2024

May 15, 2024

SELL
$1.42 - $2.3 $2,130 - $3,449
-1,500 Reduced 0.31%
482,420 $767,000
Q4 2023

Aug 16, 2024

BUY
$1.45 - $2.39 $2,175 - $3,585
1,500 Added 0.31%
483,920 $963,000
Q4 2023

Feb 13, 2024

BUY
$1.45 - $2.39 $4,234 - $6,978
2,920 Added 0.61%
483,920 $963,000
Q2 2023

Aug 14, 2023

SELL
$2.36 - $3.48 $169 - $250
-72 Reduced 0.01%
481,000 $1.39 Million
Q1 2023

May 15, 2023

SELL
$2.23 - $2.9 $8,627 - $11,220
-3,869 Reduced 0.8%
481,072 $1.17 Million
Q4 2022

Feb 14, 2023

SELL
$2.1 - $3.4 $18,280 - $29,597
-8,705 Reduced 1.76%
484,941 $1.16 Million
Q3 2022

Nov 14, 2022

SELL
$2.69 - $8.68 $14,041 - $45,309
-5,220 Reduced 1.05%
493,646 $1.34 Million
Q2 2022

Oct 27, 2022

SELL
$4.18 - $7.74 $149,246 - $276,356
-35,705 Reduced 6.68%
498,866 $2.86 Million
Q2 2022

Aug 15, 2022

SELL
$4.18 - $7.74 $149,246 - $276,356
-35,705 Reduced 6.68%
498,866 $2.86 Million
Q1 2022

Oct 27, 2022

BUY
$7.12 - $11.06 $254,219 - $394,897
35,705 Added 7.16%
534,571 $4.29 Million
Q1 2022

May 13, 2022

BUY
$7.12 - $11.06 $74,368 - $115,521
10,445 Added 1.99%
534,571 $4.29 Million
Q4 2021

Feb 14, 2022

BUY
$8.97 - $14.08 $229,084 - $359,589
25,539 Added 5.12%
524,126 $6.1 Million
Q3 2021

Nov 15, 2021

BUY
$10.25 - $15.21 $5.11 Million - $7.58 Million
498,587 New
498,587 $6.78 Million

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $40.8M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.